Quit Smoking Drugs Market Report 2026

The quit smoking drugs market size has grown rapidly in recent years. It will grow from $44.23 billion in 2025 to $50.94 billion in 2026 at a compound annual growth rate (CAGR) of 15.2%. The growth in the historic period can be attributed to increasing awareness of smoking hazards, rising prevalence of smoking-related diseases, availability of nicotine replacement therapies, government anti-smoking campaigns, growth of pharmaceutical manufacturing in emerging markets.

The quit smoking drugs market size is expected to see rapid growth in the next few years. It will grow to $90.73 billion in 2030 at a compound annual growth rate (CAGR) of 15.5%. The growth in the forecast period can be attributed to advancement in digital health solutions, rising adoption of personalized medicine, integration of ai in treatment monitoring, expansion of telemedicine services, growth of wearable health monitoring devices. Major trends in the forecast period include personalized nicotine replacement therapies, mobile health (mhealth) & smoking cessation apps, telemedicine-driven prescription support, behavioral therapy integration with drug therapy, wearable devices for monitoring cravings.

The increasing prevalence of smoking addiction is anticipated to drive the growth of the quit-smoking drug market in the future. Smoking involves inhaling and exhaling the vapors of burning plant materials such as tobacco, marijuana, hashish, and others. Quit-smoking drugs are used to reduce the desire to smoke by suppressing the craving for tobacco, and they are prescribed to manage nicotine withdrawal symptoms to aid in quitting smoking effectively. For example, in November 2025, the OECD (Organisation for Economic Co-operation and Development), a France-based international organization, reported that 14.8% of people aged 15 and older smoked daily in 2023. The highest rates of daily smoking were observed in Türkiye, Hungary, Greece, as well as in Indonesia, Bulgaria, and China, where at least one in four people smoked daily. On average, 18.5% of men smoked daily in 2023, compared to 11.4% of women. Therefore, the growing prevalence of smoking addiction is contributing to the expansion of the quit-smoking drug market.

Key companies in the quit-smoking drug market are focusing on developing new formulations and delivery methods, such as generic tablets, to strengthen their market position across regions and gain a competitive advantage. Generic varenicline tablets are non-branded versions containing varenicline tartrate, which are bioequivalent to the original branded product and used for smoking cessation therapy. For example, in January 2024, Lupin Limited, an India-based pharmaceutical company, launched new Varenicline tablets in the United States, available in 0.5 mg and 1 mg strengths. These tablets are generic versions of Chantix tablets (0.5 mg and 1 mg) from PF Prism C.V. and are used to support smoking cessation treatment. Varenicline, a partial agonist of the nicotinic acetylcholine receptor, works by stimulating the release of dopamine, which helps reduce withdrawal symptoms and cravings associated with nicotine addiction. This dual mechanism allows it to lessen the pleasurable effects of smoking while providing some stimulation to minimize withdrawal effects.

In September 2024, Dr. Reddy's Laboratories, an India-based pharmaceutical company, acquired the nicotine replacement therapy business from Haleon plc for $680 million (£500 million). The acquisition aims to strengthen Dr. Reddy's position in the global consumer healthcare market, especially by enhancing its over-the-counter (OTC) offerings and expanding its presence in key international markets outside the United States. Haleon plc is a UK-based consumer health company specializing in nicotine addiction treatments.

Major companies operating in the quit smoking drugs market are 22nd Century Group, Cipla Limited, Dr. Reddy's Laboratories, GSK Plc., Johnson & Johnson, NJOY LLC, Perrigo Company Plc, Pfizer Inc., Philip Morris International, Glenmark Pharmaceuticals Limited, Zydus Cadila Healthcare Limited, BioCorRx Inc., Ennaid Therapeutics LLC, Fertin Pharma A/S, Hikma Pharmaceuticals PLC, IntelGenx Technologies Corp., Innovus Pharmaceuticals Inc., Gilla Inc., Rusan Pharma Ltd., Novartis AG.

North America was the largest region in the quit smoking drugs market in 2025. The regions covered in the quit smoking drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the quit smoking drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on imported pharmaceutical ingredients and electronic components have posed challenges for the quit smoking drugs market by increasing production costs and delaying supply chain timelines. Segments such as e-cigarettes and nicotine inhalers are particularly affected, especially in regions like North America and Europe that rely on imported components. However, tariffs have also encouraged local manufacturing investments and innovation in cost-effective nicotine delivery solutions, potentially strengthening regional production capabilities and resilience against global supply disruption.

The quit smoking drugs market research report is one of a series of new reports that provides quit smoking drugs market statistics, including quit smoking drugs industry global market size, regional shares, competitors with a quit smoking drugs market share, detailed quit smoking drugs market segments, market trends and opportunities, and any further data you may need to thrive in the quit smoking drugs industry. This quit smoking drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Quit-smoking medications are specific treatments that help individuals stop smoking by reducing cravings and alleviating other nicotine withdrawal symptoms. These drugs deliver nicotine in a different form, such as through chewing gum or patches, for a limited time, helping to ease withdrawal symptoms and the desire to smoke.

The primary products in the quit-smoking medication category include drug therapies, electronic cigarettes, nicotine inhalers, nicotine replacement therapies, and nicotine sublingual tablets. Drug therapy involves the use of medications to treat or prevent diseases. Medications like Varenicline (Chantix), Bupropion (Zyban), and others can be found at drug stores, online pharmacies, and retail pharmacies.

The quit-smoking drugs market consists of sales of AXS-05, cytisincline, nadolol, and liraglutide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.